Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hepatocellular Carcinoma in Children: Does Modified Platinum- and Doxorubicin-Based Chemotherapy Increase Tumor Resectability and Change Outcome? Lessons Learned From the SIOPEL 2 and 3 Studies.
Murawski M, Weeda VB, Maibach R, Morland B, Roebuck DJ, Zimmerman A, Casanova M, Perilongo G, Laithier V, Kebudi R, Scopinaro MJ, Shun A, Brichard B, de Camargo B, Childs M, Aronson DC, Czauderna P. Murawski M, et al. Among authors: laithier v. J Clin Oncol. 2016 Apr 1;34(10):1050-6. doi: 10.1200/JCO.2014.60.2250. Epub 2016 Jan 25. J Clin Oncol. 2016. PMID: 26811523
Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy--results of the first French prospective study for the French Society of Pediatric Oncology.
Laithier V, Grill J, Le Deley MC, Ruchoux MM, Couanet D, Doz F, Pichon F, Rubie H, Frappaz D, Vannier JP, Babin-Boilletot A, Sariban E, Chastagner P, Zerah M, Raquin MA, Hartmann O, Kalifa C; French Society of Pediatric Oncology. Laithier V, et al. J Clin Oncol. 2003 Dec 15;21(24):4572-8. doi: 10.1200/JCO.2003.03.043. J Clin Oncol. 2003. PMID: 14673044
Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma.
Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Perilongo G, et al. Among authors: laithier v. N Engl J Med. 2009 Oct 22;361(17):1662-70. doi: 10.1056/NEJMoa0810613. N Engl J Med. 2009. PMID: 19846851 Free article. Clinical Trial.
Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study.
Zsíros J, Maibach R, Shafford E, Brugieres L, Brock P, Czauderna P, Roebuck D, Childs M, Zimmermann A, Laithier V, Otte JB, de Camargo B, MacKinlay G, Scopinaro M, Aronson D, Plaschkes J, Perilongo G. Zsíros J, et al. Among authors: laithier v. J Clin Oncol. 2010 May 20;28(15):2584-90. doi: 10.1200/JCO.2009.22.4857. Epub 2010 Apr 20. J Clin Oncol. 2010. PMID: 20406943 Clinical Trial.
Relapses in hepatoblastoma patients: clinical characteristics and outcome--experience of the International Childhood Liver Tumour Strategy Group (SIOPEL).
Semeraro M, Branchereau S, Maibach R, Zsiros J, Casanova M, Brock P, Domerg C, Aronson DC, Zimmermann A, Laithier V, Childs M, Roebuck D, Perilongo G, Czauderna P, Brugieres L. Semeraro M, et al. Among authors: laithier v. Eur J Cancer. 2013 Mar;49(4):915-22. doi: 10.1016/j.ejca.2012.10.003. Epub 2012 Nov 9. Eur J Cancer. 2013. PMID: 23146961
Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study.
Zsiros J, Brugieres L, Brock P, Roebuck D, Maibach R, Zimmermann A, Childs M, Pariente D, Laithier V, Otte JB, Branchereau S, Aronson D, Rangaswami A, Ronghe M, Casanova M, Sullivan M, Morland B, Czauderna P, Perilongo G; International Childhood Liver Tumours Strategy Group (SIOPEL). Zsiros J, et al. Among authors: laithier v. Lancet Oncol. 2013 Aug;14(9):834-42. doi: 10.1016/S1470-2045(13)70272-9. Epub 2013 Jul 4. Lancet Oncol. 2013. PMID: 23831416 Free PMC article.
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA. Brock PR, et al. Among authors: laithier v. N Engl J Med. 2018 Jun 21;378(25):2376-2385. doi: 10.1056/NEJMoa1801109. N Engl J Med. 2018. PMID: 29924955 Free PMC article. Clinical Trial.
Tumor rupture in hepatoblastoma: A high risk factor?
Pondrom M, Pariente D, Mallon B, Taque S, Branchereau S, Chardot C, Laithier V, Tabone MD, Lejeune J, Faure-Conter C, Saumet L, Vérité C, Aerts I, Brugières L, Fresneau B. Pondrom M, et al. Among authors: laithier v. Pediatr Blood Cancer. 2020 Sep;67(9):e28549. doi: 10.1002/pbc.28549. Epub 2020 Jul 3. Pediatr Blood Cancer. 2020. PMID: 32618436 Clinical Trial.
Relapses of optic pathway tumors after first-line chemotherapy.
de Haas V, Grill J, Raquin MA, Couanet D, Habrand JL, Sainte-Rose C, Laithier V, Kieffer V, Kalifa C. de Haas V, et al. Among authors: laithier v. Pediatr Blood Cancer. 2009 May;52(5):575-80. doi: 10.1002/pbc.21911. Pediatr Blood Cancer. 2009. PMID: 19148944
Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies.
Illiano M, Colinard M, Taque S, Mallon B, Larue C, Laithier V, Vérité-Goulard C, Sudour-Bonnange H, Faure-Conter C, Coze C, Aerts I, De Maricourt CD, Paillard C, Branchereau S, Brugières L, Fresneau B. Illiano M, et al. Among authors: laithier v. Hepatol Int. 2022 Feb;16(1):125-134. doi: 10.1007/s12072-021-10251-1. Epub 2021 Sep 10. Hepatol Int. 2022. PMID: 34506008
43 results